Assessment of Beta 2 Microglobulin In Patients of Diffuse Large B Cell Lymphoma As A Prognostic Marker
INTRODUCTION : Lymphoma is the proliferation of lymphoid cells, which arise as discrete tissue masses. It has been broadly divided into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). NHL contributes to about 85% of all malignant lymphomas. Diffuse large B-cell lymphoma (DLBCL) i...
Gespeichert in:
| Veröffentlicht in: | Indian journal of clinical biochemistry 2022-05, Vol.32 (S1), p.S166 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | S1 |
| container_start_page | S166 |
| container_title | Indian journal of clinical biochemistry |
| container_volume | 32 |
| creator | Gupta, Garima Ghalaut, Veena Singh Lokanathan, V Sharma, Praveen |
| description | INTRODUCTION : Lymphoma is the proliferation of lymphoid cells, which arise as discrete tissue masses. It has been broadly divided into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). NHL contributes to about 85% of all malignant lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, a heterogeneous disease with a variety of molecular aberrations and diverse clinical outcomes. Beta-2 microglobulin (?2M) is synthesized in all nucleated cells and forms the light chain subunit of the MHC class I. AIM: To determine the role of ?2M in the prognosis of patients with DLBCL so as to validate its role as a convenient biomarker. METHOD : 30 diagnosed patients with DLBCL and 30 age and sex matched healthy controls were taken. ?2M was estimated in newly diagnosed patients before initiating treatment and also in controls by ELISA. DLBCL patients were given chemotherapy following the CHOP Regimen (cyclophosphamide, hydroxydaunomyicin, oncovin, and prednisolone). Six chemotherapeutic cycles were given. Serum ?2M was repeated in cases after completion of chemotherapy. RESULTS: The levels of serum ?2M levels were found to be significantly higher in patients with DLBCL (P |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A737347981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A737347981</galeid><sourcerecordid>A737347981</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1011-a57ff5041fc8e8431d81cfcfa05652beb34a06b042aea09db30098219bd69bd73</originalsourceid><addsrcrecordid>eNptzktLxEAMB_AeFFwf3yHgyUNlptNu22N3fS10cfFxXtJppo62HWlmQb-9I3pwQUIIhN8_5CCaiTIXsSxldhQdM78KoVKRyllkKmZiHmj04AwsyCMksLZ6cl3vml1vR1iNsEFvA-Fvc2WN2TFBjVNHsIAl9T3Un8P7ixsQKoYKNiE9OvZWwxqnN5pOo0ODPdPZ7zyJnm-un5Z3cX1_u1pWddxJIWWMWW5MFh4zuqAiVbItpDbaoMjmWdJQo1IU80akCRKKsm2UEGWRyLJp56FzdRKd_9ztsKetHY3zE-rBst5WucpVmpeFDOryHxWqpcFqN5KxYb8XuNgLBOPpw3e4Y96uHh_-2i-Ie23Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Assessment of Beta 2 Microglobulin In Patients of Diffuse Large B Cell Lymphoma As A Prognostic Marker</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>Gupta, Garima ; Ghalaut, Veena Singh ; Lokanathan, V ; Sharma, Praveen</creator><creatorcontrib>Gupta, Garima ; Ghalaut, Veena Singh ; Lokanathan, V ; Sharma, Praveen</creatorcontrib><description>INTRODUCTION : Lymphoma is the proliferation of lymphoid cells, which arise as discrete tissue masses. It has been broadly divided into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). NHL contributes to about 85% of all malignant lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, a heterogeneous disease with a variety of molecular aberrations and diverse clinical outcomes. Beta-2 microglobulin (?2M) is synthesized in all nucleated cells and forms the light chain subunit of the MHC class I. AIM: To determine the role of ?2M in the prognosis of patients with DLBCL so as to validate its role as a convenient biomarker. METHOD : 30 diagnosed patients with DLBCL and 30 age and sex matched healthy controls were taken. ?2M was estimated in newly diagnosed patients before initiating treatment and also in controls by ELISA. DLBCL patients were given chemotherapy following the CHOP Regimen (cyclophosphamide, hydroxydaunomyicin, oncovin, and prednisolone). Six chemotherapeutic cycles were given. Serum ?2M was repeated in cases after completion of chemotherapy. RESULTS: The levels of serum ?2M levels were found to be significantly higher in patients with DLBCL (P<0.01). The levels were also higher significantly in patients with in advanced stages (stage III and IV) (6.12 [+ or -] 0.32?g/ml) than those with in early stages (stage I + II) (P<0.01) (3.08 [+ or -] .065?g/ml). There was also a significant decrease in serum ?2M levels after therapy, in patients who achieved remission. CONCLUSION : ?2M can be considered as a significant prognostic tool as the levels were significantly different between the pre and post--treatment groups and also declined significantly only in patients achieving remission. KEY WORDS: Lymphoma, lymphoid cells, Beta-2 microglobulin</description><identifier>ISSN: 0970-1915</identifier><language>eng</language><publisher>Springer</publisher><subject>Analysis ; Cancer ; Chemotherapy ; Medical research ; Medicine, Experimental ; Non-Hodgkin's lymphomas ; Prognosis</subject><ispartof>Indian journal of clinical biochemistry, 2022-05, Vol.32 (S1), p.S166</ispartof><rights>COPYRIGHT 2022 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids></links><search><creatorcontrib>Gupta, Garima</creatorcontrib><creatorcontrib>Ghalaut, Veena Singh</creatorcontrib><creatorcontrib>Lokanathan, V</creatorcontrib><creatorcontrib>Sharma, Praveen</creatorcontrib><title>Assessment of Beta 2 Microglobulin In Patients of Diffuse Large B Cell Lymphoma As A Prognostic Marker</title><title>Indian journal of clinical biochemistry</title><description>INTRODUCTION : Lymphoma is the proliferation of lymphoid cells, which arise as discrete tissue masses. It has been broadly divided into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). NHL contributes to about 85% of all malignant lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, a heterogeneous disease with a variety of molecular aberrations and diverse clinical outcomes. Beta-2 microglobulin (?2M) is synthesized in all nucleated cells and forms the light chain subunit of the MHC class I. AIM: To determine the role of ?2M in the prognosis of patients with DLBCL so as to validate its role as a convenient biomarker. METHOD : 30 diagnosed patients with DLBCL and 30 age and sex matched healthy controls were taken. ?2M was estimated in newly diagnosed patients before initiating treatment and also in controls by ELISA. DLBCL patients were given chemotherapy following the CHOP Regimen (cyclophosphamide, hydroxydaunomyicin, oncovin, and prednisolone). Six chemotherapeutic cycles were given. Serum ?2M was repeated in cases after completion of chemotherapy. RESULTS: The levels of serum ?2M levels were found to be significantly higher in patients with DLBCL (P<0.01). The levels were also higher significantly in patients with in advanced stages (stage III and IV) (6.12 [+ or -] 0.32?g/ml) than those with in early stages (stage I + II) (P<0.01) (3.08 [+ or -] .065?g/ml). There was also a significant decrease in serum ?2M levels after therapy, in patients who achieved remission. CONCLUSION : ?2M can be considered as a significant prognostic tool as the levels were significantly different between the pre and post--treatment groups and also declined significantly only in patients achieving remission. KEY WORDS: Lymphoma, lymphoid cells, Beta-2 microglobulin</description><subject>Analysis</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Non-Hodgkin's lymphomas</subject><subject>Prognosis</subject><issn>0970-1915</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNptzktLxEAMB_AeFFwf3yHgyUNlptNu22N3fS10cfFxXtJppo62HWlmQb-9I3pwQUIIhN8_5CCaiTIXsSxldhQdM78KoVKRyllkKmZiHmj04AwsyCMksLZ6cl3vml1vR1iNsEFvA-Fvc2WN2TFBjVNHsIAl9T3Un8P7ixsQKoYKNiE9OvZWwxqnN5pOo0ODPdPZ7zyJnm-un5Z3cX1_u1pWddxJIWWMWW5MFh4zuqAiVbItpDbaoMjmWdJQo1IU80akCRKKsm2UEGWRyLJp56FzdRKd_9ztsKetHY3zE-rBst5WucpVmpeFDOryHxWqpcFqN5KxYb8XuNgLBOPpw3e4Y96uHh_-2i-Ie23Z</recordid><startdate>20220524</startdate><enddate>20220524</enddate><creator>Gupta, Garima</creator><creator>Ghalaut, Veena Singh</creator><creator>Lokanathan, V</creator><creator>Sharma, Praveen</creator><general>Springer</general><scope>ISR</scope></search><sort><creationdate>20220524</creationdate><title>Assessment of Beta 2 Microglobulin In Patients of Diffuse Large B Cell Lymphoma As A Prognostic Marker</title><author>Gupta, Garima ; Ghalaut, Veena Singh ; Lokanathan, V ; Sharma, Praveen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1011-a57ff5041fc8e8431d81cfcfa05652beb34a06b042aea09db30098219bd69bd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Non-Hodgkin's lymphomas</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Garima</creatorcontrib><creatorcontrib>Ghalaut, Veena Singh</creatorcontrib><creatorcontrib>Lokanathan, V</creatorcontrib><creatorcontrib>Sharma, Praveen</creatorcontrib><collection>Gale In Context: Science</collection><jtitle>Indian journal of clinical biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Garima</au><au>Ghalaut, Veena Singh</au><au>Lokanathan, V</au><au>Sharma, Praveen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of Beta 2 Microglobulin In Patients of Diffuse Large B Cell Lymphoma As A Prognostic Marker</atitle><jtitle>Indian journal of clinical biochemistry</jtitle><date>2022-05-24</date><risdate>2022</risdate><volume>32</volume><issue>S1</issue><spage>S166</spage><pages>S166-</pages><issn>0970-1915</issn><abstract>INTRODUCTION : Lymphoma is the proliferation of lymphoid cells, which arise as discrete tissue masses. It has been broadly divided into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). NHL contributes to about 85% of all malignant lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, a heterogeneous disease with a variety of molecular aberrations and diverse clinical outcomes. Beta-2 microglobulin (?2M) is synthesized in all nucleated cells and forms the light chain subunit of the MHC class I. AIM: To determine the role of ?2M in the prognosis of patients with DLBCL so as to validate its role as a convenient biomarker. METHOD : 30 diagnosed patients with DLBCL and 30 age and sex matched healthy controls were taken. ?2M was estimated in newly diagnosed patients before initiating treatment and also in controls by ELISA. DLBCL patients were given chemotherapy following the CHOP Regimen (cyclophosphamide, hydroxydaunomyicin, oncovin, and prednisolone). Six chemotherapeutic cycles were given. Serum ?2M was repeated in cases after completion of chemotherapy. RESULTS: The levels of serum ?2M levels were found to be significantly higher in patients with DLBCL (P<0.01). The levels were also higher significantly in patients with in advanced stages (stage III and IV) (6.12 [+ or -] 0.32?g/ml) than those with in early stages (stage I + II) (P<0.01) (3.08 [+ or -] .065?g/ml). There was also a significant decrease in serum ?2M levels after therapy, in patients who achieved remission. CONCLUSION : ?2M can be considered as a significant prognostic tool as the levels were significantly different between the pre and post--treatment groups and also declined significantly only in patients achieving remission. KEY WORDS: Lymphoma, lymphoid cells, Beta-2 microglobulin</abstract><pub>Springer</pub><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0970-1915 |
| ispartof | Indian journal of clinical biochemistry, 2022-05, Vol.32 (S1), p.S166 |
| issn | 0970-1915 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A737347981 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; PubMed Central |
| subjects | Analysis Cancer Chemotherapy Medical research Medicine, Experimental Non-Hodgkin's lymphomas Prognosis |
| title | Assessment of Beta 2 Microglobulin In Patients of Diffuse Large B Cell Lymphoma As A Prognostic Marker |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T14%3A25%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20Beta%202%20Microglobulin%20In%20Patients%20of%20Diffuse%20Large%20B%20Cell%20Lymphoma%20As%20A%20Prognostic%20Marker&rft.jtitle=Indian%20journal%20of%20clinical%20biochemistry&rft.au=Gupta,%20Garima&rft.date=2022-05-24&rft.volume=32&rft.issue=S1&rft.spage=S166&rft.pages=S166-&rft.issn=0970-1915&rft_id=info:doi/&rft_dat=%3Cgale%3EA737347981%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A737347981&rfr_iscdi=true |